Literature DB >> 19049658

Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling.

F Bouzom1, B Walther.   

Abstract

Nowadays, 50-90% of drugs used in children have never been actually studied in this population. Consequently, either our children are often exposed to the risk of adverse drug events or to lack of efficacy, or they are unable to benefit from a number of therapeutic advances offered to adults, as no clinical study has been properly performed in children. Actually the main methods used to calculate the dose for a child are based on allometric methods taking into account different categories of age, the body weight and/or the body surface area. Unfortunately, these calculation methods consider the children as small adults, which is not the case. Physiologically based pharmacokinetics is one way to integrate the physiological changes occurring in the childhood and to anticipate their impact on the pharmacokinetic processes: absorption, distribution, metabolism and excretion/elimination. From different examples, the application of this modelling approach is discussed as a possible and valuable method to minimize the ethical and technical difficulties of conducting research in children.

Entities:  

Mesh:

Year:  2008        PMID: 19049658     DOI: 10.1111/j.1472-8206.2008.00648.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  21 in total

1.  Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment.

Authors:  Sophie Peigné; François Bouzom; Karl Brendel; Charlotte Gesson; Sylvain Fouliard; Marylore Chenel
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-11-12       Impact factor: 2.745

Review 2.  Treating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics.

Authors:  Maria D Donovan; Geraldine B Boylan; Deirdre M Murray; John F Cryan; Brendan T Griffin
Journal:  Br J Clin Pharmacol       Date:  2015-11-04       Impact factor: 4.335

3.  A predictive pharmacokinetic/pharmacodynamic model of fentanyl for analgesia/sedation in neonates based on a semi-physiologic approach.

Authors:  Esther Encinas; Rosario Calvo; John C Lukas; Valvanera Vozmediano; Monica Rodriguez; Elena Suarez
Journal:  Paediatr Drugs       Date:  2013-06       Impact factor: 3.022

4.  Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.

Authors:  Cyrielle Dumont; France Mentré; Clare Gaynor; Karl Brendel; Charlotte Gesson; Marylore Chenel
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

Review 5.  Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.

Authors:  Hannah M Jones; Kapil Mayawala; Patrick Poulin
Journal:  AAPS J       Date:  2012-12-27       Impact factor: 4.009

6.  Reversing the myths obstructing the determination of optimal age- and disease-based drug dosing in pediatrics.

Authors:  Michael D Reed
Journal:  J Pediatr Pharmacol Ther       Date:  2011-01

7.  PBPK and its Virtual Populations: the Impact of Physiology on Pediatric Pharmacokinetic Predictions of Tramadol.

Authors:  Huybrecht T'jollyn; An Vermeulen; Jan Van Bocxlaer
Journal:  AAPS J       Date:  2018-11-29       Impact factor: 4.009

8.  Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug.

Authors:  Feras Khalil; Stephanie Läer
Journal:  AAPS J       Date:  2014-01-08       Impact factor: 4.009

9.  Physiology-based IVIVE predictions of tramadol from in vitro metabolism data.

Authors:  Huybrecht T'jollyn; Jan Snoeys; Pieter Colin; Jan Van Bocxlaer; Pieter Annaert; Filip Cuyckens; An Vermeulen; Achiel Van Peer; Karel Allegaert; Geert Mannens; Koen Boussery
Journal:  Pharm Res       Date:  2014-07-22       Impact factor: 4.200

Review 10.  Developmental pharmacokinetics in pediatric populations.

Authors:  Hong Lu; Sara Rosenbaum
Journal:  J Pediatr Pharmacol Ther       Date:  2014 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.